Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Montelukast Sodium Oral Thin Films in Healthy Volunteers
NCT05528198Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2018; status: completed.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05528198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528198.